Longer disease progression milestone-free time in people with amyotrophic lateral sclerosis treated versus not treated with intravenous edaravone: results from an administrative claims analysis

Longer disease progression milestone-free time in people with amyotrophic lateral sclerosis treated versus not treated with intravenous edaravone: results from an administrative claims analysis

Aim: To estimate time-to-progression milestones in people with amyotrophic lateral sclerosis (PALS) treated versus not treated with intravenous (IV) edaravone (Radicava R IV, Mitsubishi Tanabe Pharma America [MTPA], hereafter ”IV edaravone”) in a real-world setting. Background: IV edaravone is US...

Full description

Saved in:
Bibliographic Details
Main Authors: James D Berry, Melissa Hagan, Jeffrey Zhang, Ying Liu, Malgorzata Ciepielewska
Format: Article
Language:English
Published: Becaris Publishing Limited 2025-01-01
Series:Journal of Comparative Effectiveness Research
Subjects:
administrative claims database
amyotrophic lateral sclerosis
disease progression
edaravone
milestones
propensity score matching
real-world data
restricted mean time lost
survival
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items